Lilly, Novo Skew Overall Pharma Trends With Colossal GLP-1 Sales Growth

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved into a new pharma stratosphere, far eclipsing their rivals.

Scroll to Top